Table 5.
Multiple logistic Regression: Factors influencing glycaemic control (N = 591)
| OR | 95% CI | p-value | |
|---|---|---|---|
| Family history of diabetes | |||
| No | Ref. | ||
| Yes | 1.53 | 1.06–2.23 | .025 |
| Duration of T2DM | |||
| 1–5 years | Ref. | ||
| 5–10 years | 1.10 | .66–1.81 | .717 |
| ≥ 10 years | .92 | .59–1.43 | .721 |
| BMI score | |||
| BMI < 25 (kg/m2) | Ref | ||
| BMI 25–30 | 2.08 | 1.05–4.13 | .035 |
| BMI > 30 | 2.14 | 1.12–4.07 | .021 |
| Gender | |||
| Men | Ref. | ||
| Women | 1.16 | .80–1.69 | .425 |
| Age | 1.00 | .99–1.02 | .607 |
| HDL levels (mg/dl) | |||
| HDL > 40 | Ref. | ||
| HDL ≤ 40 | 2.12 | 1.44–3.12 | < 0.001 |
| LDL levels (mg/dl) | |||
| LDL < 100 | Ref. | ||
| LDL ≥ 100 | 1.53 | 1.06–2.21 | .024 |
| Pharmacological treatment | |||
| Oral antidiabetic agents | .85 | .51–1.41 | .528 |
| Injectable antidiabetic agents | .50 | .24–1.01 | .054 |
| Combination of oral and injectable antidiabetic agents | Ref. | ||
In bold if statistically significant at the p < 0.05 or p < 0.001 level
BMI body mass index, HDL high-density lipoprotein, LDL low-density lipoprotein